US 12,239,616 B2
Food supplement and composition comprising choline butyrate salt and/or butyrylcholine
Marc Vanden Avenne, Antwerp (BE)
Assigned to ABERGAVENNY NV, Antwerp (BE)
Filed by ABERGAVENNY NV, Antwerp (BE)
Filed on Feb. 27, 2023, as Appl. No. 18/175,142.
Application 17/320,382 is a division of application No. 16/096,914, granted, now 11,007,159, issued on May 18, 2021, previously published as PCT/IB2017/052366, filed on Apr. 25, 2017.
Application 18/175,142 is a continuation of application No. 17/320,382, filed on May 14, 2021, granted, now 11,642,322.
Claims priority of application No. 2016/5290 (BE), filed on Apr. 27, 2016; and application No. 2016/5291 (BE), filed on Apr. 27, 2016.
Prior Publication US 2023/0218551 A1, Jul. 13, 2023
Int. Cl. A61K 31/14 (2006.01); A23K 20/105 (2016.01); A23K 20/158 (2016.01); A23K 20/174 (2016.01); A23L 33/10 (2016.01); A23L 33/15 (2016.01); A61K 31/19 (2006.01); A61K 31/221 (2006.01); A61P 1/00 (2006.01)
CPC A61K 31/14 (2013.01) [A23K 20/105 (2016.05); A23K 20/158 (2016.05); A23K 20/174 (2016.05); A23L 33/10 (2016.08); A23L 33/15 (2016.08); A61K 31/19 (2013.01); A61K 31/221 (2013.01); A23V 2002/00 (2013.01); A23V 2250/304 (2013.01); A61P 1/00 (2018.01)] 8 Claims
 
1. A method of improving the intestinal health of a human comprising administering a pharmaceutical composition or food supplement to the human, wherein the pharmaceutical composition or food supplement comprises, as a single active ingredient, at least 50% by weight of butyrylcholine according to formula (II),

OG Complex Work Unit Chemistry
wherein X− represents an anion,
wherein improving the intestinal health of the human comprises the selective elimination, suppression and/or regulation of at least one enteropathogen selected from the group consisting of (i) a bacterial pathogen of the genera Brachispira, Vibrio, Escherichia, Salmonella, Shigella, Klebsiella, Erwinia, Yersinia, Campylobacter, Helicobacter, Pseudomonas, Enterococcus or Clostridium, (ii) a fungal or yeast pathogen of the genera Penicillium, Aspergillus, Fusarium, Cephalosporum, Saccharomyces, Candida, Fungi Imperfecti or Hemiascomycetes, and (iii) a viral pathogen of the genera Norovirus or Rotavirus and wherein the pharmaceutical composition or food supplement administered at a daily dose of butyrylcholine according to formula (II) is 50 mg to 1 g per day.